Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03557307 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate Efficacy and Safety of Benralizumab in Reducing Oral Corticosteroid Use in Adult Patients With Severe Asthma
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 598
- Enrollment target
NCT03557307 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 598 participants.
The verdict
NCT03557307, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 598 participants
- Enrollment target
Study Summary
This is a study designed to evaluate efficacy and safety of Benralizumab in reducing the Oral Corticosteroid (OCS) use in adult patients with severe asthma who are receiving OCS with or without additional asthma controller medications.
Interventions
- BIOLOGICAL Benralizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 598 participants |
| Start Date | 2018-08-01 |
| Est. Completion | 2022-03-24 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03557307
The ClinicalTrials.gov registry entry for NCT03557307 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 598 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Benralizumab is the first listed.
NCT03557307 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03557307 about?
NCT03557307 is a clinical study titled "Study to Evaluate Efficacy and Safety of Benralizumab in Reducing Oral Corticosteroid Use in Adult Patients With Severe Asthma". This is a study designed to evaluate efficacy and safety of Benralizumab in reducing the Oral Corticosteroid (OCS) use in adult patients with severe asthma who are receiving OCS with or without additional asthma controller medications.
What is the current status of trial NCT03557307?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 598 participants. The study started on 2018-08-01. Estimated completion is 2022-03-24.
What interventions are being tested in trial NCT03557307?
The interventions under investigation include: Benralizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT03557307?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.